Genmab — Oktober 2022
-
“The Japanese system is complex and it’s dynamic, but I would argue that also the US system is very complex and dynamic. I mean, there was recent legislation, which is potentially completely changing the reimbursement of medicines in the US,” he said. “Europe is even more difficult to navigate,” he continued, explaining that it takes years for some countries to set prices for new medicines. “I would say that Japan is not necessarily more complex than other systems,” he added...
-
In the meantime, Dr van de Winkel also spoke about ways to address the challenge of rising drug prices seen in tandem with the diversification of modalities, stressing the need to curb R&D and manufacturing costs to ensure access to medicines. “I think we need to develop medicines more effectively and in shorter periods of time in the future,” said the CEO, explaining that Genmab is looking into an approach to work with data science companies to shorten the development process thereby...
-
In Japan, some Genmab-originated medicines are already available through partners, but not via its Japan outpost. Farthest along in development towards its first stand-alone product approval are two drug candidates. One is tisotumab vedotin, an antibody-drug conjugate (ADC) for cervical cancer, which is approved in the US under the brand name of Tivdak. The other is the bispecific antibody epcoritamab for the treatment of non-Hodgkin’s lymphoma...
-
While setting up an independent system in Japan, Genmab appears to be more cautious about its move in China. “This is, of course, a market that we don’t want to ignore,” he said, but he added that in China, the company will be working with partners based on licensing strategies. [SLUT]
-
Tillykke til Genmab med den 6. godkendelse. Nu har Genmab også opdateret hjemmesiden efter 2 måneders betænkningstid
-
Selskaber shortet på det danske aktiemarked pr. 24/10-2022 https://www.proinvestor.com/boards/107280
-
Kesimpta Q3 289 mUSD (Q2: 239) + 21 %. Det skulle gerne ende +1 mia. USD når året er omme
-
"strong sales growth mainly driven by US launch momentum" fra rapportering
-
Scancell signs exclusive deal with cancer giant Genmab for anti-glycan antitbody https://www.proactiveinvestors.co.uk/companies/news/996315/scancell-signs-exclusive-deal-with-genmab-for-anti-glycan-antitbody-996315.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind